GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK
Hub to Advance Global Vaccine and Immuno-Oncology Development
ATLANTA, GA - March 12, 2025 ( NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in the development of immunotherapies and vaccines, today announced its initial steps toward establishing a strategic presence in Europe, with the UK as its initial footprint. This move aligns with the Company's commitment to advancing its vaccine and immunotherapy pipeline through global collaborations.
Efforts are underway to identify a UK location best suited to align with GeoVax's development and corporate strategy. The Company already has several established connections in the UK and broader European region, including:
Scientific Expertise: Professor Teresa Lambe, a principal investigator at the Oxford Vaccine Group, recently joined GeoVax's Scientific Advisory Board. Professor Lambe played a pivotal role in the development of the Oxford/AstraZeneca COVID-19 vaccine and has extensive experience in vaccine design and evaluation.
Manufacturing Partnerships: GeoVax maintains an existing contract development and manufacturing organization (CDMO) relationship with Oxford Biomedica PLC (Oxford, UK), as well as additional collaborations with Oxford Biomedica (France), with facilities in Strasbourg and Lyon.
Technology Licensing: The Company has a broad licensing agreement with ProBioGen AG (Berlin, Germany) to utilize their AGE1 continuous avian cell line for the manufacture of MVA vaccines.
European Collaborations: GeoVax currently collaborates with multiple European-based service providers and UK academic partners, reinforcing the strategic rationale for establishing a presence within the region.
To support this initiative, GeoVax is working closely with Professor Teresa Lambe and clinical investigators and scientists in Oxford and other academic centers across the UK to develop preclinical, translational, and clinical projects supporting its pipeline. Additionally, Dr. Deborah Spencer, a highly regarded expert in industry-academic partnerships and public health development, has recently been retained to facilitate and coordinate initiatives in the UK and Europe.
Establishing a strategic presence in Europe will support GeoVax's infectious disease vaccine development efforts and play a key role in advancing Gedeptin(R), the Company's lead immuno-oncology candidate. Currently in clinical development for the treatment of advanced head and neck cancers, Gedeptin is anticipated to be further developed for use with immune checkpoint inhibitors as a potential treatment for various other solid tumors. GeoVax holds worldwide rights to Gedeptin for all indications.
'Expanding our presence into Europe represents a critical milestone for GeoVax as we continue to develop innovative solutions for infectious diseases and oncology, especially in building upon our initial UK footprint,' said David Dodd, President and CEO of GeoVax. 'The globally recognized expertise of our key European collaborators and partners will significantly enhance our research and development capabilities. This expansion underscores our commitment to global collaboration and innovation in both vaccine and immuno-oncology development. As we accelerate the development of our infectious disease vaccine candidates and Gedeptin, we look forward to providing continued updates.'
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin(R) combined with an immune checkpoint inhibitor is planned. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
678-384-7220
212-698-8696
Media Contact:
202-779-0929
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Ukraine plots fracking revolution
Ukraine is working to unleash natural gas fracking with the goal of becoming a major exporter and revolutionising Europe's energy market. In plans critical to Volodymyr Zelensky's hopes of a post-war economic recovery, ministers in Kyiv are scrambling to lure private investment and gain access to new drilling technology to access the country's vast untapped shale gas resources. According to sources close to Kyiv, officials are racing to attract 'foreign technology and highly experienced subsoil users', with a focus on unconventional shale resources in western Ukraine. The hunt for cash - as revealed by the independent news platform Energy Flux - is being conducted in parallel to the rare earth minerals deal struck between Donald Trump and President Zelensky in April, which will allow the US to exploit Ukraine's natural resources, including aluminium, graphite, oil and natural gas. The priority is to rapidly revitalise Ukraine's ailing gas sector after a gruelling winter saw roughly 40pc of production capacity taken out by a fierce Russian campaign of drone and missile strikes. The attacks forced Ukraine to draw heavily on its gas stocks, which ended winter almost entirely depleted. But Ukraine's Ministry of Energy believes it is possible to refill the country's cavernous underground storage facilities and even produce a surplus for export 'within 18 months', according to a senior government source. Ukraine already has some experience with advanced drilling technology for old wells and has since carried out experimental trials that 'confirm its potential' for fracking, they said. However, to unlock Ukraine's shale reserves, the country needs to attract more investment and newer kit, primarily from America. 'Development and production can be quickly developed using available gas infrastructure with connections to the EU gas market that make it very attractive,' the source added. 'Ukraine has enough deposits of traditional gas to cover its own consumption and to become a net exporter, and shale gas production has quite a profound effect on its development.' Such a turnaround would help transform the fortunes of Europe's energy markets, which remain on edge following the loss of Russian pipeline gas exports via Ukraine at the start of 2025. Refilling Ukraine's depleted gas storage – the largest in Europe, at 32bn cubic metres – is one of the main factors tightening energy markets in Central and Eastern Europe ahead of next winter. Ukraine's gas stocks are today just 7pc full compared to the EU average of 50pc. Efforts to pipe natural gas from Southern and Eastern Europe into Ukraine have also been thwarted by red tape and a lack of market cohesion. However, if Ukraine could unleash its own shale revolution and create a surplus for export, the need to keep pumping European gas into Ukraine would effectively disappear overnight. It would also help reduce Europe's reliance on costly liquefied natural gas (LNG) supplies from overseas. Gas-starved Europe leaned heavily on LNG after Gazprom, the Kremlin-backed energy giant, halted exports to the EU following Vladimir Putin's full-scale invasion of Ukraine in 2022. Ukrainian shale gas exports, if scaled up quickly, would erase a large chunk of European energy demand currently being met by LNG, potentially sparking a sharp drop in energy prices around the world. However, Kyiv's proposed fracking revolution hinges largely on the country's ability to secure overseas investment. Officials from Ukraine's Ministry of Energy are tapping Western diplomatic ties to find private capital funds with a high tolerance for risk to bankroll drilling and bring in technology partners. A senior government team attended the Baku Energy Forum in Azerbaijan last week in part to promote Ukraine's potential as a shale hub. Speaking at the event, one high-ranking statesman said the Lviv-Lublin geological area that straddles the Ukraine-Poland border is 'superior on the Ukrainian side' thanks to higher porosity and lower clay content, making it 'better for fracking'. The most promising prospect is the Oleska (Olesskaya) shale block, which contains an estimated 0.8 to 1.5 trillion cubic metres of shale gas resources – enough to meet Ukraine's domestic needs for decades. How much of this resource is economically recoverable is an open question. Chevron walked away from a 50pc interest in the Oleska project in 2014 before drilling could begin. Chevron's stated reason for leaving was not because of political instability or lack of resources, but rather Kyiv's failure to enact specific tax reforms necessary to enable shale gas foreign investment. Now, the Zelensky administration is moving to streamline operations and reduce bureaucratic hurdles that previously deterred foreign investors. Ownership of the Olesskaya production sharing agreement (PSA) was transferred in April 2025 from government holding company Nadra Ukraine to Ukraine's largest oil and gas producer, Ukrnafta. The move signalled a strategic shift in the country's approach to fracking, particularly in the Oleska block. Ukrnafta is a state-owned enterprise following the nationalisation of strategic industries and declaration of martial law in 2022, which remains in force to this day. Attracting significant private capital into Ukrainian shale exploration would normally be impossible under these circumstances. However, the source said there are laws in place to ensure they can be overwritten. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Business Insider
an hour ago
- Business Insider
Nvidia or Palantir: Morgan Stanley Selects the Superior AI Stock to Buy
A smart investor is always on the lookout for growth sectors, places where the economy is primed to boom and where consequent opportunities are riding high. Right now, few sectors are offering the strong growth potential of artificial intelligence (AI). Confident Investing Starts Here: In just a few short years, AI – and particularly generative and agentic AI – has become the 'shiny new thing' on the cutting edge of high-tech. The entry of AI is rapidly transforming the tech industry, and it is making inroads into numerous other areas. Data management, content creation, publishing – we've only begun to find out what AI can do, and we can only imagine what it will do. A report from UN Trade & Development points out that the world's AI market, which was estimated at $189 billion in 2023, will expand 25x by 2033 to reach $4.8 trillion. AI's growth will bring with it gains for companies across a wide spectrum of fields, including development, applications, hardware, infrastructure, and power generation. Such rapid growth is creating new opportunities for investors. The challenge won't be finding one – it'll be choosing the right one. That's where Morgan Stanley's analysts come in. They've zeroed in on two tech titans that have become synonymous with AI innovation: Nvidia (NASDAQ:NVDA) and Palantir (NASDAQ:PLTR). Both are riding the AI wave, but Morgan Stanley is making a clear call on which one stands out as the better buy right now. Let's take a closer look. Nvidi a Nvidia stands at the forefront of Wall Street's tech revolution. As a dominant force among the 'Magnificent 7' and boasting a $3.45 trillion market cap, it's not only the largest of the tech mega-cap – it's the biggest publicly traded company in the U.S. The AI boom, which took off in late 2022 with the debut of ChatGPT, put Nvidia in the spotlight. As the top supplier of high-performance GPUs, the company was well-positioned to meet the explosive demand for AI-capable chips – and that sent NVDA shares soaring 660% over the past three years. However, even a juggernaut like Nvidia isn't immune to shifting market dynamics. After an extraordinary run, the company's stock momentum has started to cool amid rising volatility this year. One key challenge stems from the lingering effects of President Trump's tariff policies. The chip industry is deeply intertwined with global supply chains, and Nvidia's exposure to East Asia has made it vulnerable to tariff risks. That may be easing now, as both China and the EU have entered into trade talks with the White House. Yet, Nvidia isn't standing still. The company continues to push the boundaries of innovation, doubling down on emerging technologies to maintain its leadership in the AI race. This past May, Nvidia unveiled the world's largest dedicated quantum computing research supercomputer, the ABCI-Q, hosted at the Global Research and Development Center for Business by Quantum-AI Technology (G-QuAT). The new system is already integrated with Nvidia's open-source hybrid computing platform CUDA-Q. A second new development was made public last week. Nvidia announced that its Blackwell architecture, designed to power the latest AI platforms, showed superior performance on the latest rounds of the MLPerf Training, a key benchmark used to rate the capabilities of new AI systems. In Nvidia's last earnings report, covering fiscal 1Q26, company CEO Jensen Huang noted that the company's breakthrough Blackwell products are in full production and went on to outline the potential for AI to continue supporting strong results: 'Global demand for NVIDIA's AI infrastructure is incredibly strong. AI inference token generation has surged tenfold in just one year, and as AI agents become mainstream, the demand for AI computing will accelerate.' Turning to the company's financial results for the quarter, we find that Nvidia's revenue came in at $44.1 billion, up 69% year-over-year and $810 million better than had been expected. The company's non-GAAP EPS figure, at 81 cents, was 6 cents per share above the forecasts. Data center revenue, at $39.1 billion, was the main revenue driver and was up 73% year-over-year. Nvidia's gross margin for the quarter was reported at approximately 61%. For 5-star analyst Joseph Moore, the key point for investors to remember about Nvidia is that the future looks good. The Morgan Stanley analyst writes in his note on this chip maker: 'Racks get better from here. China is entirely derisked, at least for direct shipments, and we are optimistic that there will be some path to monetize at least a portion of that demand. Gross margins have bottomed and are improving to the mid 70s, sustainably. And every customer commentary confirms that customers waiting for these new technologies have left demand on the table. So our confidence in durable demand drives is quite high. We think that our numbers are conservative given the variables at play, and we see a high probability of continued upward revisions.' Moore's comments support his Overweight (i.e., Buy) rating on NVDA stock, while his $170 price target points toward a one-year upside potential of 20%. (To watch Moore's track record, click here) Overall, Nvidia has earned a Strong Buy consensus rating from the Street's analysts, based on 40 reviews that include 35 Buys, 4 Holds, and 1Sell. The stock is priced at $141.72 and its $172.36 average price target implies a ~22% upside in the next 12 months. (See NVDA stock forecast) Palantir Technologies Palantir is another standout in the AI space. Founded in 2003 by venture capitalist Peter Thiel, the company has built a strong reputation as a leader in data analytics and software solutions. Like Nvidia, Palantir has leveraged its unique capabilities to ride the wave of the AI boom, and the results have been striking. Over the past three years, its stock has skyrocketed 1,291%, including a 69% gain year-to-date. These gains haven't come by chance. Palantir stock's growth is rooted in the strength of its data management and analysis tools, which are used by businesses, non-profits, and government agencies alike. At the center of its offerings is the AI Platform (AIP), a solution that blends advanced AI capabilities with human-driven decision-making. One of its key strengths lies in its accessibility – users can interact with the platform using natural language, without needing coding expertise. AIP also supports multilingual inputs and translation frameworks, making it easier for users around the world to engage with its tools. Palantir can currently boast more than 760 customers, from both the public and private sectors. The company's AI-powered data platforms are popular with big businesses, and Palantir can count such names as Stellantis and BP among its users, as well as the US Department of Defense. In May, Palantir received a $795 million contract modification to its Maven Smart System agreement with the Army, extending support through 2029. The company is also among the short‑listed firms – alongside SpaceX, Lockheed Martin – and others, being considered for President Trump's $175 billion Golden Dome missile defense program. On the financial side, Palantir has been singularly successful at generating strong revenues and earnings. In 1Q25, the last period reported, the company had a top line of $883.9 million, representing 39% year-over-year growth and beating the forecast by $21.72 million. At the bottom line, Palantir's EPS came to 13 cents in non-GAAP terms, matching analyst expectations. The company proved successful at closing large deals during the quarter, including 31 deals worth at least $10 million. Despite this strength, some caution is warranted. Morgan Stanley's Sanjit Singh remains confident in Palantir's fundamentals but cautions that the valuation may be stretched after such a strong run. 'Palantir continues to prove out that it is one of the clear AI winners in software which has translated to accelerating top-line growth of 30%+ and a rule of 40 score (revenue growth + operating margin) of 83%. While this represents elite level performance in software, the current valuation of ~95x CY27 FCF makes underwriting a return on Palantir shares extremely challenging. As a result, we remain EW and await a better entry point before getting more bullish,' Singh noted. Singh's Equal Weight (i.e., Hold) rating comes with a $98 price target, implying a potential 25% drop from current levels. It's safe to say that his ideal entry point lies somewhere south of that. (To view Singh's track record, click here) Morgan Stanley's view aligns with the broader Street consensus. Palantir holds a Hold rating overall, based on 18 recent analyst recommendations: 3 Buys, 11 Holds, and 4 Sells. The stock is currently trading at $127.72, while the average price target stands at $100.13, implying a potential ~22% downside over the coming year. (See PLTR stock forecast) With the facts laid out, the Morgan Stanley analysts come to a clear conclusion: Both of these AI stocks are solid performers, but Nvidia is the superior choice to buy right now. To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
an hour ago
- Yahoo
European Market Insights: genOway Société anonyme And 2 Promising Penny Stocks
The European market has shown resilience with the pan-European STOXX Europe 600 Index rising by 0.90%, buoyed by a slowdown in inflation and easing monetary policy from the European Central Bank. As investors navigate these evolving conditions, penny stocks—often representing smaller or newer companies—continue to capture interest for their potential growth at accessible price points. Despite being an outdated term, penny stocks remain relevant as they can offer opportunities for those seeking to invest in financially strong companies with promising prospects. Name Share Price Market Cap Financial Health Rating Mistral Iberia Real Estate SOCIMI (BME:YMIB) €1.01 €22M ★★★★★☆ KebNi (OM:KEBNI B) SEK1.996 SEK541.22M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.61 SEK270.7M ★★★★★★ Cellularline (BIT:CELL) €2.95 €62.22M ★★★★★☆ Fondia Oyj (HLSE:FONDIA) €4.78 €17.87M ★★★★★★ Abak (WSE:ABK) PLN4.00 PLN10.78M ★★★★★★ Bredband2 i Skandinavien (OM:BRE2) SEK2.38 SEK2.28B ★★★★☆☆ Hifab Group (OM:HIFA B) SEK3.62 SEK220.24M ★★★★★★ Deceuninck (ENXTBR:DECB) €2.175 €300.29M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.936 €31.34M ★★★★★★ Click here to see the full list of 447 stocks from our European Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: genOway Société anonyme is a biotechnology company that develops and commercializes custom genetically modified mouse, rat, and cell line models globally, with a market cap of €31.44 million. Operations: The company's revenue is derived entirely from its biotechnology segment, amounting to €27.53 million. Market Cap: €31.44M genOway Société anonyme, with a market cap of €31.44 million, has shown consistent revenue growth, reporting €22.06 million in sales for 2024, up from €20.05 million the previous year. The company maintains strong financial health with short-term assets exceeding both its short and long-term liabilities and a satisfactory net debt to equity ratio of 3.4%. Despite not outperforming the biotech industry in earnings growth last year, genOway's profitability has improved over five years at an impressive annual rate of 67.1%, supported by high-quality earnings and stable weekly volatility at 6%. Click here and access our complete financial health analysis report to understand the dynamics of genOway Société anonyme. Learn about genOway Société anonyme's historical performance here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Kudelski SA, with a market cap of CHF67.34 million, offers digital access and security solutions for digital television and interactive applications across Switzerland, the United States, France, Germany, Austria, and other international markets. Operations: The company's revenue is primarily derived from three segments: Digital TV ($227.83 million), Cybersecurity ($108.47 million), and Internet of Things ($47.43 million). Market Cap: CHF67.34M Kudelski SA, with a market cap of CHF67.34 million, operates in digital access and security solutions across multiple markets. Despite being unprofitable with increasing losses over the past five years, it holds strong financials with short-term assets exceeding liabilities and more cash than debt. The seasoned management team and board bring stability, while recent partnerships in IoT and AI sectors highlight strategic growth efforts. Notably, Kudelski's collaboration with Stotz Equipment enhances asset visibility solutions without subscription fees, potentially driving future revenue streams within diverse industries like agriculture and construction. The stock trades significantly below estimated fair value compared to peers. Navigate through the intricacies of Kudelski with our comprehensive balance sheet health report here. Evaluate Kudelski's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: PCC Exol S.A. manufactures and distributes surfactants both in Poland and internationally, with a market cap of PLN452.76 million. Operations: The company's revenue is primarily derived from its Specialty Chemicals segment, totaling PLN996.33 million. Market Cap: PLN452.76M PCC Exol S.A., with a market cap of PLN452.76 million, shows promising financials as its short-term assets exceed both long-term and short-term liabilities. The company's earnings growth of 23.1% over the past year surpasses its five-year average and outpaces the broader Chemicals industry growth rate. However, while interest payments are well covered by EBIT, operating cash flow covers only 17% of debt, indicating potential liquidity concerns. Despite a high net debt to equity ratio of 54.1%, PCC Exol maintains high-quality earnings with no significant shareholder dilution recently and offers a price-to-earnings ratio below the Polish market average. Get an in-depth perspective on PCC Exol's performance by reading our balance sheet health report here. Explore historical data to track PCC Exol's performance over time in our past results report. Take a closer look at our European Penny Stocks list of 447 companies by clicking here. Interested In Other Possibilities? These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:ALGEN SWX:KUD and WSE:PCX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
